- Home
- CMBM vs BLRX Comparison
CMBM vs BLRX Comparison
Compare CMBM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- BLRX
- Stock Information
- Founded
- CMBM 2011
- BLRX 2003
- Country
- CMBM United States
- BLRX Israel
- Employees
- CMBM N/A
- BLRX N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- BLRX Health Care
- Exchange
- CMBM Nasdaq
- BLRX Nasdaq
- Market Cap
- CMBM 50.8M
- BLRX 54.1M
- IPO Year
- CMBM 2019
- BLRX 2011
- Fundamental
- Price
- CMBM $1.45
- BLRX $0.49
- Analyst Decision
- CMBM Buy
- BLRX Strong Buy
- Analyst Count
- CMBM 6
- BLRX 2
- Target Price
- CMBM $6.13
- BLRX $11.50
- AVG Volume (30 Days)
- CMBM 64.9K
- BLRX 319.5K
- Earning Date
- CMBM 10-31-2024
- BLRX 11-18-2024
- Dividend Yield
- CMBM N/A
- BLRX N/A
- EPS Growth
- CMBM N/A
- BLRX N/A
- EPS
- CMBM N/A
- BLRX N/A
- Revenue
- CMBM $171,535,000.00
- BLRX $17,048,000.00
- Revenue This Year
- CMBM N/A
- BLRX N/A
- Revenue Next Year
- CMBM $19.77
- BLRX N/A
- P/E Ratio
- CMBM N/A
- BLRX N/A
- Revenue Growth
- CMBM N/A
- BLRX N/A
- 52 Week Low
- CMBM $1.40
- BLRX $0.43
- 52 Week High
- CMBM $6.50
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- CMBM 35.18
- BLRX 34.05
- Support Level
- CMBM $1.71
- BLRX $0.43
- Resistance Level
- CMBM $1.48
- BLRX $0.56
- Average True Range (ATR)
- CMBM 0.13
- BLRX 0.05
- MACD
- CMBM -0.03
- BLRX -0.01
- Stochastic Oscillator
- CMBM 7.35
- BLRX 23.96
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.